<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007037</article-id><article-id pub-id-type="pmc">PMC11860497</article-id><article-id pub-id-type="doi">10.3390/v17020282</article-id><article-id pub-id-type="publisher-id">viruses-17-00282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Berberine, a Natural Compound That Demonstrates Antiviral Effects Against Ostreid Herpesvirus 1 Infection in <italic toggle="yes">Anadara broughtonii</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Hui-Gang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-17-00282" ref-type="aff">1</xref><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Mao-Le</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-viruses-17-00282" ref-type="aff">1</xref><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jing-Li</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-viruses-17-00282" ref-type="aff">1</xref><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Cui-Ping</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-17-00282" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiang</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-7136-1254</contrib-id><name><surname>Huang</surname><given-names>Bo-Wen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4685-1076</contrib-id><name><surname>Xin</surname><given-names>Lu-Sheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref><xref rid="c1-viruses-17-00282" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5476-2455</contrib-id><name><surname>Bai</surname><given-names>Chang-Ming</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-viruses-17-00282" ref-type="aff">2</xref><xref rid="af3-viruses-17-00282" ref-type="aff">3</xref><xref rid="af4-viruses-17-00282" ref-type="aff">4</xref><xref rid="c1-viruses-17-00282" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>De la Torre</surname><given-names>Juan</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Abd-Alla</surname><given-names>Adly</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00282"><label>1</label>Qingdao Nucleic Acid Rapid Detection Engineering Research Center, Qingdao Key Laboratory of Nucleic Acid Rapid Detection, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China; <email>kanghuigang0123@163.com</email> (H.-G.K.); <email>liuli000315@gmail.com</email> (M.-L.W.); <email>wjl19863763762@163.com</email> (J.-L.W.); <email>mcp169@163.com</email> (C.-P.M.)</aff><aff id="af2-viruses-17-00282"><label>2</label>State Key Laboratory of Mariculture Biobreeding and Sustainable Goods, Key Laboratory of Maricultural Organism Disease Control, Ministry of Agriculture, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao 266071, China; <email>zhxiang1997@126.com</email> (X.Z.); <email>huangbw@ysfri.ac.cn</email> (B.-W.H.)</aff><aff id="af3-viruses-17-00282"><label>3</label>Laboratory for Marine Fisheries Science and Food Production Processes, Qingdao Marine Science and Technology Center, Qingdao 266237, China</aff><aff id="af4-viruses-17-00282"><label>4</label>Shandong Center of Technology Innovation for Oyster Seed Industry, Qingdao 266105, China</aff><author-notes><corresp id="c1-viruses-17-00282"><label>*</label>Correspondence: <email>xinlusheng@126.com</email> (L.-S.X.); <email>baicm@ysfri.ac.cn</email> (C.-M.B.)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>282</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Ostreid herpesvirus 1 (OsHV-1) infection is the primary viral disease responsible for large-scale mortality in bivalve mollusks worldwide, and effective strategies to control the outbreaks of this disease are still lacking. Berberine (BBR), a plant-derived alkaloid, has demonstrated antiviral activity against various vertebrate viruses, while its potential antiviral effects on molluscan herpesviruses remain to be fully elucidated. Therefore, the present study sought to investigate the potential of berberine hydrochloride (BBH) against OsHV-1 infection in blood clams (<italic toggle="yes">Anadara broughtonii</italic>). The most optimal BBH concentration was figured out according to virus replication and mortality rates during in vivo experimental infection. Quantitative PCR and reverse transcription quantitative PCR were utilized to monitor the OsHV-1 genomic copy numbers and viral gene transcription levels during the development of OsHV-1 infection in the BBH-treated and control groups. The results demonstrated that a 3 mg/L BBH bath immersion significantly suppressed OsHV-1 replication in blood clams. During the early stage of infection (24 h), BBH treatment significantly reduced the expression of OsHV-1 open reading frames (ORFs) related to early enzymes, putative membrane proteins, and nucleocapsid proteins. At 96 h post-infection, all untreated blood clams died, whereas the survival rate of BBH-treated individuals increased to 46.67%. This study provides preliminary evidence for the inhibitory effects of BBH on OsHV-1, paving the way for the development of pharmacological control technologies for OsHV-1 infections.</p></abstract><kwd-group><kwd>OsHV-1</kwd><kwd>BBH</kwd><kwd><italic toggle="yes">Anadara broughtonii</italic></kwd><kwd>antiviral response</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>32073014</award-id><award-id>32403054</award-id></award-group><award-group><funding-source>Central Public-interest Scientific Institution Basal Research Fund, CAFS</funding-source><award-id>2023TD30</award-id></award-group><award-group><funding-source>earmarked fund for CARS</funding-source><award-id>CARS-49</award-id></award-group><award-group><funding-source>Shandong Postdoctoral Science Foundation</funding-source><award-id>SDCX-ZG-202303048</award-id></award-group><funding-statement>This research was funded by the National Natural Science Foundation of China, grant No. 32073014 and No. 32403054, the Central Public-interest Scientific Institution Basal Research Fund, CAFS, grant No. 2023TD30, the earmarked fund for CARS, grant No. CARS-49, and the Shandong Postdoctoral Science Foundation, grant No. SDCX-ZG-202303048.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00282"><title>1. Introduction</title><p>Ostreid herpesvirus 1 (OsHV-1), a member of the family <italic toggle="yes">Malacoherpesviridae</italic> and genus <italic toggle="yes">Ostreavirus</italic>, is one of the most prevalent viral pathogens affecting bivalves on a global scale [<xref rid="B1-viruses-17-00282" ref-type="bibr">1</xref>]. Since its discovery, OsHV-1 has been responsible for significant economic losses in the shellfish aquaculture industry [<xref rid="B2-viruses-17-00282" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00282" ref-type="bibr">3</xref>]. Bivalves represent a pivotal group of marine organisms, playing a crucial role in marine ecosystems and supporting important fisheries and aquaculture industries worldwide [<xref rid="B4-viruses-17-00282" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00282" ref-type="bibr">5</xref>]. The first documented cases of herpesvirus infections in invertebrates occurred in adult oysters along the U.S. East Coast in 1972 [<xref rid="B6-viruses-17-00282" ref-type="bibr">6</xref>]. In 1999, herpesvirus particles linked to high mortality were first successfully purified from juvenile oysters in France [<xref rid="B7-viruses-17-00282" ref-type="bibr">7</xref>]. The presence of OsHV-1 has been detected in various bivalve species (e.g., <italic toggle="yes">Crassostrea gigas</italic>, <italic toggle="yes">Ostrea angasi</italic>, <italic toggle="yes">Ruditapes decussatus</italic>, <italic toggle="yes">Pecten maximus</italic>) across Europe, North America, Australia, and other regions, leading to large-scale outbreaks and mortality events [<xref rid="B8-viruses-17-00282" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-00282" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00282" ref-type="bibr">10</xref>,<xref rid="B11-viruses-17-00282" ref-type="bibr">11</xref>]. Several variants of OsHV-1, including OsHV-1&#x003bc;var, Acute Viral Necrotic Virus (AVNV) of scallops, and OsHV-1-SB, have emerged globally, posing significant challenges to the control of molluscan herpesvirus infections [<xref rid="B12-viruses-17-00282" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00282" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-00282" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00282" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00282" ref-type="bibr">16</xref>,<xref rid="B17-viruses-17-00282" ref-type="bibr">17</xref>]. Research indicates that OsHV-1 infection compromises the antioxidant system in oysters, causing cellular damage, exacerbating immunosuppression, and ultimately triggering opportunistic bacterial infections [<xref rid="B18-viruses-17-00282" ref-type="bibr">18</xref>,<xref rid="B19-viruses-17-00282" ref-type="bibr">19</xref>]. OsHV-1 outbreaks typically occur during the warmer summer months, with mortality rates in infected juvenile Pacific oysters often exceeding 80% [<xref rid="B20-viruses-17-00282" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00282" ref-type="bibr">21</xref>]. In recent years, <italic toggle="yes">Anadara broughtonii</italic> has been identified as a susceptible host of OsHV-1, with mass mortality events linked to this viral infection [<xref rid="B15-viruses-17-00282" ref-type="bibr">15</xref>]. Since the initial detection of OsHV-1 in <italic toggle="yes">A. broughtonii</italic> in 2012, it has become the foremost cause of large-scale mortality in this species [<xref rid="B22-viruses-17-00282" ref-type="bibr">22</xref>]. Despite the advancement in knowledge of OsHV-1, there is currently no efficient or cost-effective treatment to combat this viral disease. Consequently, there is an urgent need to explore and develop effective control interventions to mitigate the economic losses incurred as a result of this viral disease.</p><p>Berberine (BBR), an isoquinoline alkaloid, is a natural compound that occurs in various medicinal plants, including <italic toggle="yes">Coptis</italic> chinensis, <italic toggle="yes">Phellodendron amurense</italic>, and <italic toggle="yes">Berberis</italic> species [<xref rid="B23-viruses-17-00282" ref-type="bibr">23</xref>]. BBR has a long history in traditional herbal medicine, where it is frequently used to treat gastrointestinal inflammation in humans [<xref rid="B24-viruses-17-00282" ref-type="bibr">24</xref>]. BBR has low toxicity and minimal side effects, demonstrating unique biochemical and pharmacological activities, including antibacterial, antiviral, anti-inflammatory, anticancer, and metabolic regulatory effects [<xref rid="B25-viruses-17-00282" ref-type="bibr">25</xref>]. The molecular structure of BBR consists of a tetracyclic system with an N-benzyl tetrahydroisoquinoline backbone and an additional C13 carbon bridge. The complexity of this structure allows BBR to interact with multiple biological targets, thereby exerting its pharmacological effects [<xref rid="B26-viruses-17-00282" ref-type="bibr">26</xref>]. Berberine hydrochloride (BBH) is the hydrochloride salt form of BBR. This form of BBR is able to effectively penetrate the cell membranes and enter cells, which is a factor in its wide-ranging utilization due to its high bioavailability. BBR has been shown to possess significant antiviral activity against a range of viruses, including herpes simplex virus (HSV), influenza virus, human cytomegalovirus (HCMV), and enterovirus [<xref rid="B27-viruses-17-00282" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00282" ref-type="bibr">28</xref>,<xref rid="B29-viruses-17-00282" ref-type="bibr">29</xref>]. The primary mechanism of action of BBR involves its interaction with intracellular targets, particularly enzymes and DNA. Studies have shown that BBR inhibits HCMV replication by interfering with the transactivation activity of the immediate-early 2 (IE2) protein [<xref rid="B27-viruses-17-00282" ref-type="bibr">27</xref>]. Furthermore, BBR has been demonstrated to act early in the replication cycle of HSV, inhibiting HSV-induced NF-&#x003ba;B activation and c-Jun N-terminal kinase (JNK) phosphorylation [<xref rid="B28-viruses-17-00282" ref-type="bibr">28</xref>]. Additionally, BBH has been reported in studies on viral diseases in aquatic animals. For example, BBH has been shown to inhibit viral gene transcription and to suppress Cyprinid herpesvirus 2 (CyHV-2) replication in RyuF-2 cells [<xref rid="B30-viruses-17-00282" ref-type="bibr">30</xref>]. However, the effects of BBH on molluscan herpesviruses remain largely unexplored.</p><p>The present study evaluated the efficacy of BBH in suppressing OsHV-1 replication through bath treatments administered to OsHV-1-infected blood clams. The findings of this study seek to assess the potential of BBH as an antiviral agent for the prevention and control of mollusk diseases in aquaculture.</p></sec><sec id="sec2-viruses-17-00282"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-00282"><title>2.1. Drugs and Animals</title><p>The berberine hydrochloride (BBH) capsules were obtained from Yunnan Baiyao Group Co., Ltd., Kunming, China, with a dosage of 0.1 g per capsule. The experimental animals, <italic toggle="yes">Anadara broughtonii</italic>, were a batch of 300 healthy blood clams (shell length 54.86&#x02013;67.93 mm) purchased in January 2024 from a bivalve farm in Rizhao, Shandong Province, China. These blood clams were caught from the wild population in the Yellow Sea. Following their transportation to the aquaculture facility of the Yellow Sea Fisheries Research Institute (YSFRI), the blood clams were accommodated in 100 L tanks (10 blood clams per tank), with aerated, filtered seawater supplied and half of the water replaced daily. The animals were provided with sufficient bivalve feed. Throughout the experiment, the salinity and temperature of the seawater were maintained at 30 &#x000b1; 1 ppt and 18 &#x000b1; 1 &#x000b0;C, respectively. Following a 2-week acclimation period, 30 blood clams were randomly selected, all of which tested negative for OsHV-1. Prior to the commencement of the experiment, the blood clams were subjected to 2-week fasting, a condition that was intended to induce a state of starvation followed by maximum filtration activity [<xref rid="B31-viruses-17-00282" ref-type="bibr">31</xref>]. The experiment was conducted in strict accordance with the ethical guidelines of the Animal Ethics Committee of the Yellow Sea Fisheries Research Institute, CAFS.</p></sec><sec id="sec2dot2-viruses-17-00282"><title>2.2. OsHV-1 Infection Experiment</title><p>The tissue homogenate was prepared using the standard inoculation protocol described by Schikorski et al. [<xref rid="B32-viruses-17-00282" ref-type="bibr">32</xref>]. Briefly, the mantle tissues of OsHV-1-infected blood clams were collected and homogenized in sterile seawater. The mixture was centrifuged briefly at 1000 rpm and 4 &#x000b0;C, and the supernatant was retained. The resulting viral inoculum was filtered sequentially through filters with pore sizes of 5 &#x003bc;m, 2 &#x003bc;m, 0.45 &#x003bc;m, and 0.22 &#x003bc;m, then stored at 4 &#x000b0;C for later use. Due to the small and concealed adductor muscle of the blood clams, the viral inoculum was injected into the foot, which is exposed and easier to handle. In the infection experiment, the blood clams were anesthetized with 70 g/L MgCl<sub>2</sub>, and 100 &#x003bc;L of the viral inoculum (adjusted to 1 &#x000d7; 10<sup>4</sup> copies/&#x003bc;L) was injected into the foot of each blood clam.</p></sec><sec id="sec2dot3-viruses-17-00282"><title>2.3. BBH Medicated Bath</title><p>Since blood clams are filter-feeding animals, we adopted an immersion method for drug administration. To ensure the complete dissolution of the drug in seawater, berberine hydrochloride was sonicated. The employment of ultrasonic technology has been demonstrated to enhance the solubility of drugs, particularly those that are inherently water-insoluble. This method accelerates dissolution and enhances drug bioavailability [<xref rid="B33-viruses-17-00282" ref-type="bibr">33</xref>]. Berberine hydrochloride powder was added to a 50 mL centrifuge tube with 30 mL of sterile seawater and placed in a sonicator (model: SB25-12D, manufacturer: NingBo Scientz Biotechnology Co., Ltd., Ningbo, China) for 10 min at 20 kHz and subjected to intermittent shaking (at a frequency of 5 min) during the sonication process to ensure complete dissolution of all particles, and this was continued until no visible undissolved particles were observed. In order to enhance the absorption of the drug by the blood clams, an innovation was introduced in the method of drug delivery. Concentrated diatoms, used to feed the blood clams, were added to the sonicated BBH solution, facilitating complete integration of the drug and promoting its adsorption onto the diatoms [<xref rid="B34-viruses-17-00282" ref-type="bibr">34</xref>].</p><p>To determine the safe drug concentration of BBR in the blood clams [<xref rid="B35-viruses-17-00282" ref-type="bibr">35</xref>], different amounts of berberine hydrochloride (0.1 g, 0.3 g, 0.6 g, and 0.9 g) were added to the tanks, resulting in final concentrations of 1 mg/L, 3 mg/L, 6 mg/L, and 9 mg/L, respectively, according to previous reports and the weight of the blood clams [<xref rid="B30-viruses-17-00282" ref-type="bibr">30</xref>]. After culturing for 7 days under identical conditions, we performed a preliminary toxicity assessment at the individual level by observing the behavior, appearance, and mortality of blood clams treated with different drug concentrations. Both the protective and therapeutic effects of BBH on vertebrate herpesviruses have been reported previously [<xref rid="B27-viruses-17-00282" ref-type="bibr">27</xref>,<xref rid="B28-viruses-17-00282" ref-type="bibr">28</xref>,<xref rid="B29-viruses-17-00282" ref-type="bibr">29</xref>,<xref rid="B30-viruses-17-00282" ref-type="bibr">30</xref>]. To determine the most effective measure for OsHV-1 control, BBH bath was administered both before and after experimental infection. The blood clams were randomly assigned to enter the medicated bath group or the control group. One day prior to the injection of OsHV-1, the prepared berberine hydrochloride was distributed evenly in the tanks as a bath for the blood clams. After the viral infection, berberine hydrochloride was administered continuously to the group tanks containing the medicated bath, with the seawater being replaced every 24 h and the drug being re-administered. No drug exposure was applied to the control group.</p></sec><sec id="sec2dot4-viruses-17-00282"><title>2.4. Tissue Sample Collection and Mortality Assessment</title><p>Five tanks with 10 clams in each tank were assigned to each treatment group, with three tanks designated for the collection of tissue samples and the remaining two for the monitoring of mortality. Three blood clams from each medicated bath group and the control group were collected at 12, 24, 36, 48, 60, and 72 h. The blood clams were dissected, and hemolymph was collected from the adductor muscle sinus of each blood clam using a 23 G needle and a 5 mL syringe [<xref rid="B36-viruses-17-00282" ref-type="bibr">36</xref>]. The hemolymph from each group was divided into three equal portions, after which it was subjected to centrifugation at 800 rpm for 5 min at 4 &#x000b0;C. The supernatant was discarded. Then, 1 mL of Trizol (Invitrogen, Carlsbad, CA, USA) was added to two aliquots of each sample which were then immediately frozen in liquid nitrogen; all samples were stored at &#x02212;80 &#x000b0;C for RNA and DNA extraction and further analysis [<xref rid="B37-viruses-17-00282" ref-type="bibr">37</xref>].</p></sec><sec id="sec2dot5-viruses-17-00282"><title>2.5. DNA Extraction and Quantification of OsHV-1 DNA</title><p>DNA was extracted from frozen hemocyte samples using the TIANamp&#x02122; Marine Animal DNA Kit (Tiangen Biotech, Beijing, China) according to the manufacturer&#x02019;s protocol. DNA purity and quantity were assessed using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA). The OsHV-1 DNA copy number was determined using quantitative PCR (qPCR) based on the protocol published by Bai et al., as fully described in the references [<xref rid="B15-viruses-17-00282" ref-type="bibr">15</xref>]. Briefly, the amplification was performed in a 20 &#x000b5;L reaction mixture, including 10 &#x000b5;L of 2&#x000d7; FastStart Essential DNA Probe Master Mix (Roche), 0.8 &#x000b5;L of each primer (10 &#x000b5;M), 0.4 &#x000b5;L of TaqMan<sup>&#x000ae;</sup> Probe (10 &#x000b5;M), 1.6 &#x000b5;L of template DNA, and 6.4 &#x000b5;L of DEPC water. Each DNA sample was quantified using the CFX Connect&#x02122; Real-Time System (Bio-Rad Laboratories, Inc., Hercules, CA, USA), with each qPCR analysis performed in triplicate. The OsHV-1 DNA copy number was evaluated as the average number of OsHV-1 DNA copies per ng of total DNA.</p></sec><sec id="sec2dot6-viruses-17-00282"><title>2.6. Total RNA Extraction and cDNA Synthesis</title><p>Total RNA was extracted from 50 mg of each tissue sample using TRIzol reagent (Invitrogen) according to the manufacturer&#x02019;s protocol. cDNA was synthesized using gDNA Eraser-treated total RNA as a template, according to the guidelines for reverse transcription PCR (RT-PCR) and reverse transcription reagents (TaKaRa, Shiga, Japan). The synthesis reaction was performed at 37 &#x000b0;C for 15 min, followed by heating at 85 &#x000b0;C for 5 s to terminate the reaction. The cDNA mixture was diluted at a ratio of 1:10 and stored at &#x02212;80 &#x000b0;C.</p></sec><sec id="sec2dot7-viruses-17-00282"><title>2.7. RT-qPCR Measurement of Relative Expression Levels of OsHV-1 ORFs</title><p>Real-time quantitative PCR (RT-qPCR) analysis was conducted using the Bio-Rad CFX Connect Real-Time System (Bio-Rad Laboratories), with each RT-qPCR sample analyzed in triplicate. The total amplification reaction volume was 20 &#x003bc;L, consisting of 5 &#x003bc;L of diluted cDNA template (1:10), 10 &#x003bc;L of 2&#x000d7; SYBR Green PCR Mix (Takara), 0.8 &#x003bc;L of forward and reverse primers (250 nM), and 3.4 &#x003bc;L of distilled water. The cycling conditions were as follows: 95 &#x000b0;C for 1 min, followed by 95 &#x000b0;C for 10 s, and 60 &#x000b0;C for 30 s for a total of 40 cycles. The specificity of the primers was assessed using a melt curve, where the temperature was increased from 60 &#x000b0;C to 95 &#x000b0;C (at 0.5 &#x000b0;C per 10 s). The forward and reverse primers were designed using Primer Premier 5 software (PREMIER Biosoft) and synthesized by Genechem Co., Ltd. (Shanghai, China).</p><p>Based on the expression analysis of blood clam housekeeping genes under OsHV-1 challenge, EF-1&#x003b1; and RL15 were selected as housekeeping genes for the RT-qPCR normalization of viral gene expression. The Ct difference between viral genes and EF-1&#x003b1; provides the relative expression levels of the viral genes [<xref rid="B38-viruses-17-00282" ref-type="bibr">38</xref>]. To investigate viral gene expression, 26 genes were selected from the 124 ORFs of OsHV-1 based on their protein function or structure. These genes fall into five gene/family categories (<xref rid="viruses-17-00282-t001" ref-type="table">Table 1</xref>) [<xref rid="B1-viruses-17-00282" ref-type="bibr">1</xref>,<xref rid="B39-viruses-17-00282" ref-type="bibr">39</xref>]: (i) seven ORFs encoding enzymes (ORF 7, ORF 20, ORF 27, ORF 34, ORF 49, ORF 51, ORF 67); (ii) four ORFs of the RING gene family (ORF 9, ORF 42, ORF 53, ORF 87, with ORF 42 and ORF 87 containing a BIR domain) [<xref rid="B26-viruses-17-00282" ref-type="bibr">26</xref>]; (iii) twelve ORFs encoding membrane proteins (ORF 16, ORF 25, ORF 36, ORF 41, ORF 54, ORF 57, ORF 59, ORF 68, ORF 72, ORF 80, ORF 84, ORF 88); (iv) one ORF encoding a capsid protein (ORF 104); and (v) two ORFs encoding unknown proteins (ORF 11, ORF 37). <xref rid="viruses-17-00282-t001" ref-type="table">Table 1</xref> provides primer information for the selected OsHV-1 ORFs and blood clam housekeeping genes used in this RT-qPCR experiment.</p></sec><sec id="sec2dot8-viruses-17-00282"><title>2.8. Data Analysis</title><p>Survival rates, viral genome copy numbers, and relative expression levels of OsHV-1 ORFs were compared between the medicated bath group and the control group (non-drug exposed) at various time points of OsHV-1 infection (12 h, 24 h, 36 h, 48 h, 60 h, and 72 h). The 2<sup>&#x02212;&#x02206;&#x02206;CT</sup> method was applied to accurately analyze the relative expression levels of ORFs [<xref rid="B40-viruses-17-00282" ref-type="bibr">40</xref>]. Blood clam housekeeping genes (<xref rid="viruses-17-00282-t001" ref-type="table">Table 1</xref>) were used as internal references to normalize the relative expression levels between samples. The average relative expression for each group was calculated using the 2<sup>&#x02212;&#x02206;&#x02206;CT</sup> method, with the control group used for normalization. The relative expression results of ORFs are expressed as the mean &#x000b1; standard error. Statistical analysis was performed using IBM SPSS Statistics 19.0, and the relevant data were plotted using GraphPad Prism software (version 10.2.1).</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00282"><title>3. Results</title><sec id="sec3dot1-viruses-17-00282"><title>3.1. Survival Rate of Blood Clams</title><p>Following the injection of the viral inoculum into the blood clams, mortality rates were monitored at 12 h intervals in order to assess the survival of blood clams in the BBH bath groups (with concentrations of 1 mg/L, 3 mg/L, 6 mg/L, and 9 mg/L) and the control group (without drug exposure). Following OsHV-1 infection, the survival rates of blood clams in the BBH bath groups were higher than those in the control group. Among them, blood clams infected with OsHV-1 and treated with a 3 mg/L BBH bath exhibited the most significant therapeutic effect, with a survival rate of 46.67% at 96 h post-infection (<xref rid="viruses-17-00282-f001" ref-type="fig">Figure 1</xref>). However, the control group, which received no drug treatment, showed the first signs of mortality at 36 hpi. By 60 hpi, the remaining blood clams were in a moribund state, and the survival rate had dropped to zero by 72 h. In contrast, the 3 mg/L BBH group showed mortality only after 60 hpi.</p></sec><sec id="sec3dot2-viruses-17-00282"><title>3.2. OsHV-1 DNA Copy Number</title><p>Virus DNA quantification was performed on the 3 mg/L BBH bath group and the control group at different time points post-OsHV-1 infection. The qPCR results showed significant differences (<italic toggle="yes">p</italic> &#x0003c; 0.05) in OsHV-1 DNA copy numbers between the medicated bath group and the control group at 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h post-infection. The bath with a concentration of 3 mg/L BBH led to a substantial reduction in OsHV-1 replication (<xref rid="viruses-17-00282-f002" ref-type="fig">Figure 2</xref>). In the control group, a significant increase in OsHV-1 viral particle growth was observed, primarily during the mid-infection period (48 h). In contrast, the medicated bath group exhibited a delay in viral particle replication, with a significant increase in viral particle production only beginning at the later stages of infection (72 h). These findings suggest that the BBH bath can effectively interfere with OsHV-1 viral DNA replication in infected blood clams, particularly during the early stages, where viral particle proliferation is significantly inhibited. Symptoms generally appeared when the viral load reached a threshold (generally considered to be around 10<sup>4</sup> copies/ng DNA) [<xref rid="B41-viruses-17-00282" ref-type="bibr">41</xref>]. In the 3 mg/L BBH treatment group, the viral load remained below this threshold until 60 hpi, which explains why mortality did not occur in this group until after 60 hpi.</p></sec><sec id="sec3dot3-viruses-17-00282"><title>3.3. OsHV-1 ORFs Relative Expression</title><p>In this study, a selection of 26 OsHV-1 ORFs from five genomic/family groups was made on the basis of their protein function, structure, and gene family classification (<xref rid="viruses-17-00282-t001" ref-type="table">Table 1</xref>). The relative expression of these ORFs was then assessed in the 3 mg/L BBH bath group and the control group using real-time RT-PCR. The results showed that at 24 h post-infection (early stage), the expression levels of OsHV-1 ORFs were significantly reduced in the BBH bath group compared to the control group (<italic toggle="yes">p</italic> &#x0003c; 0.05). This finding is consistent with the results of the OsHV-1 DNA copy number assay. The variation in the relative expression of OsHV-1 ORFs between the BBH bath group and the control group was more evident at 24 h post-infection (early stage) than at 72 h (late stage) (<xref rid="viruses-17-00282-f003" ref-type="fig">Figure 3</xref>).</p><p>It is noteworthy that specific ORFs encoding enzymes or proteins fulfill pivotal functions in the process of viral particle replication. For example, ORF7 is hypothesized to encode a member of the DNA primase family, ORF25, ORF36, ORF72, and ORF80 are hypothesized to encode membrane proteins, and ORF104 is hypothesized to encode the nucleocapsid protein. A statistically significant disparity in the relative expression levels of these ORFs (<italic toggle="yes">p</italic> &#x0003c; 0.05) was observed between the BBH bath group and the control group (<xref rid="viruses-17-00282-f004" ref-type="fig">Figure 4</xref>). Furthermore, the expression levels of different ORFs at the same time point (24 h post-infection) also showed distinct variations, which may be related to the characteristics of the proteins they encode [<xref rid="B42-viruses-17-00282" ref-type="bibr">42</xref>].</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00282"><title>4. Discussion</title><p>A substantial body of research has been dedicated to the exploration of the antiviral properties of numerous herbal medicines in Traditional Chinese Medicine (TCM). The bioactive molecules present in these herbs, including plant alkaloids, flavonoids, and terpenoids, are recognized as pivotal elements contributing to their therapeutic effects [<xref rid="B43-viruses-17-00282" ref-type="bibr">43</xref>]. Plant-derived alkaloids have been shown to be effective in reducing viral load by interfering with viral adsorption and invasion of host cells, as well as by modulating immune responses to enhance the host&#x02019;s antiviral capacity. Berberine (BBR), a natural alkaloid with broad-spectrum antiviral activity, has demonstrated significant potential in the control of viral diseases in aquatic animals. Berberine has typically been used by oral administration in fish and has shown a dose-dependent antiviral effect [<xref rid="B30-viruses-17-00282" ref-type="bibr">30</xref>]. Due to the unique feeding habits of bivalves, we administered BBH by bath treatment and also demonstrated the inhibitory effect on OsHV-1 replication, although the benefit of the drug is not dose dependent in the present study. We proposed that the solubility of BBH in seawater was responsible for the unexpected results. Fine particles could be detected in tanks with concentrations of 6 mg/mL and 9 mg/mL BBH. These particles may interfere with the filter feeding of clams, and thus the treatment effect.</p><p>The mechanism by which BBR exerts its antiviral effects is through the modulation of inflammation, oxidative stress, and immune responses; one such key mechanism is the regulation of the NF-&#x003ba;B pathway. BBR has been shown to downregulate virus-induced NF-&#x003ba;B activation and prevent the degradation of the endogenous NF-&#x003ba;B inhibitor I&#x003ba;B&#x003b1; [<xref rid="B44-viruses-17-00282" ref-type="bibr">44</xref>]. BBH may help to protect crucian carp from CyHV-2 infection by negatively regulating the NF-&#x003ba;B signaling pathway and its downstream inflammatory cytokines [<xref rid="B45-viruses-17-00282" ref-type="bibr">45</xref>]. BBR has demonstrated therapeutic potential in the treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). During SARS-CoV infection, the NF-&#x003ba;B signaling pathway is activated by viral proteins such as nsp1, nsp2, nsp7, and the spike protein, and BBR has been shown to inhibit this pathway [<xref rid="B46-viruses-17-00282" ref-type="bibr">46</xref>]. In addition to this, BBR has been shown to exert anti-neuroinflammatory effects and neuroprotective properties in the central nervous system (CNS). It has been demonstrated that BBR can inhibit the excessive production of pro-inflammatory cytokines and nitric oxide (NO), thereby protecting the CNS from neurodegenerative diseases by suppressing neuroinflammation and improving neurological outcomes [<xref rid="B23-viruses-17-00282" ref-type="bibr">23</xref>]. BBR has antiviral preventive effects, which are crucial for pre-treatment and for enhancing therapeutic efficacy. Studies show that BBR regulates ROS production and inhibits viral replication by downregulating autophagy, thereby preventing fatal enterovirus 71 (EV71) neuroinfection [<xref rid="B47-viruses-17-00282" ref-type="bibr">47</xref>]. In addition, Hong et al. demonstrated that BBR inhibits Hepatitis C virus (HCV) replication by targeting the binding of the E2 glycoprotein and blocking HCV attachment and entry, thus suggesting that BBR may be a promising candidate for developing entry inhibitors to prevent and treat HCV infection [<xref rid="B48-viruses-17-00282" ref-type="bibr">48</xref>]. Furthermore, BBH has been shown to be capable of systemically inhibiting CyHV-2 gene transcription and suppressing its replication in RyuF-2 cells, thereby demonstrating a dose-dependent protective effect against CyHV-2 infection in crucian carp [<xref rid="B30-viruses-17-00282" ref-type="bibr">30</xref>]. Specifically, we introduced a BBH bath treatment method with the aim of effectively inhibiting OsHV-1 replication in blood clams.</p><p>Proteins encoded by specific ORFs in the OsHV-1 genome play a crucial role in viral invasion and early replication. They facilitate the specific binding of the virus to host cells and promote viral replication within host cells, leading to viral proliferation. For example, the putative membrane proteins encoded by ORF25, ORF41, and ORF72 appear to be involved in the interaction between OsHV-1 and host cells, and these membrane proteins are believed to be related to the attachment of the virus to oyster cells, facilitating viral entry into host cells [<xref rid="B49-viruses-17-00282" ref-type="bibr">49</xref>]. Furthermore, the analysis of the interactions between viral membrane proteins and host&#x02013;cell surface molecules has shown that ORF25 and ORF72 can interact synergistically with actin and tubulin, respectively [<xref rid="B50-viruses-17-00282" ref-type="bibr">50</xref>]. Morga et al. were the first to report the detection of viral DNA in Pacific oyster hemocytes 1 h post-exposure, with significant increases at 18 and 24 h. Viral transcript levels also varied depending on the analyzed ORFs [<xref rid="B42-viruses-17-00282" ref-type="bibr">42</xref>]. Furthermore, it has been hypothesized that certain OsHV-1-encoded proteins may also possess immunomodulatory functions, thereby enabling the virus to evade the host immune system by modulating immune responses. Two dUTPase-like proteins (ORF 27 and ORF 75) of OsHV-1 are highly expressed at the transcriptomic level, with the potential to disrupt the immune response of Pacific oysters and inhibit host antiviral responses, thus enhancing viral survival [<xref rid="B51-viruses-17-00282" ref-type="bibr">51</xref>]. Furthermore, the apoptosis inhibitory protein (IAP) family members ORF87 and ORF106 have been shown to maximize the amplification of viral particles in the early stages of infection by inhibiting TNF-mediated cell apoptosis in Pacific oyster cells [<xref rid="B52-viruses-17-00282" ref-type="bibr">52</xref>]. Previous studies have reported that OsHV-1, ORF42, and ORF87 are significantly upregulated in the early stages of infection (4 h post-infection), limiting the host&#x02013;cell apoptotic response [<xref rid="B39-viruses-17-00282" ref-type="bibr">39</xref>]. Recent studies using long-read sequencing and multi-omics analysis techniques have facilitated the in-depth analysis of key protein-coding genes in the OsHV-1 genome, with a particular focus on the conservation of transcriptional structures related to the major capsid protein (MCP, ORF104) and capsid maturation protease (ORF107) isoforms, further revealing the conserved expression strategies of the viral capsid maturation module and the virus&#x02019;s evasion of the host ADAR antiviral defense mechanism [<xref rid="B53-viruses-17-00282" ref-type="bibr">53</xref>]. In this study, particularly during the initial phases of infection (24 h), the relative expression of OsHV-1 ORFs was considerably diminished in blood clams subjected to BBH bath treatment. This observation indicates that BBH may potently impede OsHV-1 invasion and early replication in blood clams, thereby decelerating the progression of the disease. While BBH has been shown to be effective in increasing the resistance of blood clams to OsHV-1 infection, further research is needed to understand the molecular mechanisms by which BBH regulates the resistance of blood clams to OsHV-1.</p></sec><sec sec-type="conclusions" id="sec5-viruses-17-00282"><title>5. Conclusions</title><p>The present study demonstrates the efficacy of BBH in suppressing OsHV-1 replication in <italic toggle="yes">Anadara broughtonii</italic>, particularly during the initial phases of infection. This inhibition is achieved by blocking the transcription of early viral genes and membrane protein genes involved in viral attachment, thereby markedly enhancing the antiviral response of <italic toggle="yes">A. broughtonii</italic> and increasing its survival rate. This finding provides scientific evidence to support the potential application of BBH as an antiviral agent in the aquaculture industry. In the future, we must further validate BBH&#x02019;s antiviral effect against OsHV-1 infection in mollusk production.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Pei-Jun Li from Tianjin Agricultural University for providing assistance during experimental infection and sample collection.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.-S.X. and C.-M.B.; methodology, H.-G.K., M.-L.W., J.-L.W. and L.-S.X.; validation, X.Z. and B.-W.H.; formal analysis, H.-G.K., M.-L.W. and J.-L.W.; resources, C.-M.B.; data curation, L.-S.X. and C.-M.B.; writing&#x02014;original draft preparation, H.-G.K.; writing&#x02014;review and editing, C.-P.M., L.-S.X. and C.-M.B.; project administration, C.-M.B.; funding acquisition, B.-W.H., L.-S.X. and C.-M.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Ethical review and approval were waived for this study because the blood clams have no central nervous system.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The authors confirm that the data supporting the findings of this study are available within the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00282"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davison</surname><given-names>A.J.</given-names></name>
<name><surname>Trus</surname><given-names>B.L.</given-names></name>
<name><surname>Cheng</surname><given-names>N.</given-names></name>
<name><surname>Steven</surname><given-names>A.C.</given-names></name>
<name><surname>Watson</surname><given-names>M.S.</given-names></name>
<name><surname>Cunningham</surname><given-names>C.</given-names></name>
<name><surname>Deuff</surname><given-names>R.L.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>A novel class of herpesvirus with bivalve hosts</article-title><source>J. Gen. Virol.</source><year>2005</year><volume>86</volume><issue-part>Pt 1</issue-part><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1099/vir.0.80382-0</pub-id><pub-id pub-id-type="pmid">15604430</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00282"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davison</surname><given-names>A.J.</given-names></name>
<name><surname>Eberle</surname><given-names>R.</given-names></name>
<name><surname>Ehlers</surname><given-names>B.</given-names></name>
<name><surname>Hayward</surname><given-names>G.S.</given-names></name>
<name><surname>McGeoch</surname><given-names>D.J.</given-names></name>
<name><surname>Minson</surname><given-names>A.C.</given-names></name>
<name><surname>Pellett</surname><given-names>P.E.</given-names></name>
<name><surname>Roizman</surname><given-names>B.</given-names></name>
<name><surname>Studdert</surname><given-names>M.J.</given-names></name>
<name><surname>Thiry</surname><given-names>E.</given-names></name>
</person-group><article-title>The order Herpesvirales</article-title><source>Arch. Virol.</source><year>2009</year><volume>154</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1007/s00705-008-0278-4</pub-id><pub-id pub-id-type="pmid">19066710</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00282"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Lorgeril</surname><given-names>J.</given-names></name>
<name><surname>Lucasson</surname><given-names>A.</given-names></name>
<name><surname>Petton</surname><given-names>B.</given-names></name>
<name><surname>Toulza</surname><given-names>E.</given-names></name>
<name><surname>Montagnani</surname><given-names>C.</given-names></name>
<name><surname>Clerissi</surname><given-names>C.</given-names></name>
<name><surname>Vidal-Dupiol</surname><given-names>J.</given-names></name>
<name><surname>Chaparro</surname><given-names>C.</given-names></name>
<name><surname>Galinier</surname><given-names>R.</given-names></name>
<name><surname>Escoubas</surname><given-names>J.-M.</given-names></name>
<etal/>
</person-group><article-title>Immune-suppression by OsHV-1 viral infection causes fatal bacteraemia in Pacific oysters</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4215</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06659-3</pub-id><pub-id pub-id-type="pmid">30310074</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00282"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Ford</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Infectious diseases of marine molluscs and host responses as revealed by genomic tools</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2016</year><volume>371</volume><elocation-id>20150206</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2015.0206</pub-id><pub-id pub-id-type="pmid">26880838</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00282"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theuerkauf</surname><given-names>S.J.</given-names></name>
<name><surname>Barrett</surname><given-names>L.T.</given-names></name>
<name><surname>Alleway</surname><given-names>H.K.</given-names></name>
<name><surname>Costa-Pierce</surname><given-names>B.A.</given-names></name>
<name><surname>St. Gelais</surname><given-names>A.</given-names></name>
<name><surname>Jones</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Habitat value of bivalve shellfish and seaweed aquaculture for fish and invertebrates: Pathways, synthesis and next steps</article-title><source>Rev. Aquac.</source><year>2021</year><volume>14</volume><fpage>54</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/raq.12584</pub-id></element-citation></ref><ref id="B6-viruses-17-00282"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farley</surname><given-names>C.A.</given-names></name>
<name><surname>Banfield</surname><given-names>W.G.</given-names></name>
<name><surname>Kasnic</surname><given-names>G.</given-names></name>
<name><surname>Foster</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Oyster Herpes-Type Virus</article-title><source>Science</source><year>1972</year><volume>178</volume><fpage>759</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1126/science.178.4062.759</pub-id><pub-id pub-id-type="pmid">5082840</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00282"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le Deuff</surname><given-names>R.-M.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Purification and partial genome characterization of a herpes-like virus infecting the Japanese oyster, Crassostrea gigas</article-title><source>J. Gen. Virol.</source><year>1999</year><volume>80</volume><fpage>1317</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-80-5-1317</pub-id><pub-id pub-id-type="pmid">10355779</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00282"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arzul</surname><given-names>I.</given-names></name>
<name><surname>Nicolas</surname><given-names>J.L.</given-names></name>
<name><surname>Davison</surname><given-names>A.J.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>French scallops: A new host for ostreid herpesvirus-1</article-title><source>Virology</source><year>2001</year><volume>290</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1186</pub-id><pub-id pub-id-type="pmid">11883198</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00282"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>S.C.</given-names></name>
<name><surname>Fidler</surname><given-names>A.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Primers for PCR-based detection of ostreid herpes virus-1 (OsHV-1): Application in a survey of New Zealand molluscs</article-title><source>Aquaculture</source><year>2007</year><volume>272</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2007.07.224</pub-id></element-citation></ref><ref id="B10-viruses-17-00282"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arzul</surname><given-names>I.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
<name><surname>Lipart</surname><given-names>C.</given-names></name>
<name><surname>Davison</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Evidence for interspecies transmission of oyster herpesvirus in marine bivalves</article-title><source>J. Gen. Virol.</source><year>2001</year><volume>82</volume><issue-part>Pt 4</issue-part><fpage>865</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-82-4-865</pub-id><pub-id pub-id-type="pmid">11257192</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00282"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hine</surname><given-names>P.</given-names></name>
</person-group><article-title>Herpesviruses associated with mortalities among hatchery-reared larval Pacific oysters Crassostrea gigas</article-title><source>Dis. Aquat. Org.</source><year>1992</year><volume>12</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.3354/dao012135</pub-id></element-citation></ref><ref id="B12-viruses-17-00282"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segarra</surname><given-names>A.</given-names></name>
<name><surname>Pepin</surname><given-names>J.F.</given-names></name>
<name><surname>Arzul</surname><given-names>I.</given-names></name>
<name><surname>Morga</surname><given-names>B.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Detection and description of a particular Ostreid herpesvirus 1 genotype associated with massive mortality outbreaks of Pacific oysters, Crassostrea gigas, in France in 2008</article-title><source>Virus Res.</source><year>2010</year><volume>153</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2010.07.011</pub-id><pub-id pub-id-type="pmid">20638433</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00282"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martenot</surname><given-names>C.</given-names></name>
<name><surname>Oden</surname><given-names>E.</given-names></name>
<name><surname>Travaill&#x000e9;</surname><given-names>E.</given-names></name>
<name><surname>Malas</surname><given-names>J.P.</given-names></name>
<name><surname>Houssin</surname><given-names>M.</given-names></name>
</person-group><article-title>Detection of different variants of Ostreid Herpesvirus 1 in the Pacific oyster, Crassostrea gigas between 2008 and 2010</article-title><source>Virus Res.</source><year>2011</year><volume>160</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2011.04.012</pub-id><pub-id pub-id-type="pmid">21600247</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00282"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
</person-group><article-title>Complete genome sequence of acute viral necrosis virus associated with massive mortality outbreaks in the Chinese scallop, Chlamys farreri</article-title><source>Virol. J.</source><year>2013</year><volume>10</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-10-110</pub-id><pub-id pub-id-type="pmid">23566284</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00282"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Qiu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
</person-group><article-title>Identification and characterization of ostreid herpesvirus 1 associated with massive mortalities of Scapharca broughtonii broodstocks in China</article-title><source>Dis. Aquat. Organ.</source><year>2016</year><volume>118</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3354/dao02958</pub-id><pub-id pub-id-type="pmid">26865236</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00282"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burge</surname><given-names>C.A.</given-names></name>
<name><surname>Friedman</surname><given-names>C.S.</given-names></name>
<name><surname>Kachmar</surname><given-names>M.L.</given-names></name>
<name><surname>Humphrey</surname><given-names>K.L.</given-names></name>
<name><surname>Moore</surname><given-names>J.D.</given-names></name>
<name><surname>Elston</surname><given-names>R.A.</given-names></name>
</person-group><article-title>The first detection of a novel OsHV-1 microvariant in San Diego, California, USA</article-title><source>J. Invertebr. Pathol.</source><year>2021</year><volume>184</volume><fpage>107636</fpage><pub-id pub-id-type="doi">10.1016/j.jip.2021.107636</pub-id><pub-id pub-id-type="pmid">34116033</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00282"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xia</surname><given-names>J.</given-names></name>
<name><surname>Bai</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
</person-group><article-title>Complete genome sequence of Ostreid herpesvirus-1 associated with mortalities of Scapharca broughtonii broodstocks</article-title><source>Virol. J.</source><year>2015</year><volume>12</volume><fpage>110</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0334-0</pub-id><pub-id pub-id-type="pmid">26209441</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00282"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunselman</surname><given-names>E.</given-names></name>
<name><surname>Manrique</surname><given-names>D.</given-names></name>
<name><surname>Burge</surname><given-names>C.A.</given-names></name>
<name><surname>Allard</surname><given-names>S.</given-names></name>
<name><surname>Daniel</surname><given-names>Z.</given-names></name>
<name><surname>Mitta</surname><given-names>G.</given-names></name>
<name><surname>Petton</surname><given-names>B.</given-names></name>
<name><surname>Gilbert</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Temperature and microbe mediated impacts of the San Diego Bay ostreid herpesvirus (OsHV-1) microvariant on juvenile Pacific oysters</article-title><source>Sustain. Microbiol.</source><year>2024</year><volume>1</volume><elocation-id>qvae014</elocation-id><pub-id pub-id-type="doi">10.1093/sumbio/qvae014</pub-id></element-citation></ref><ref id="B19-viruses-17-00282"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delisle</surname><given-names>L.</given-names></name>
<name><surname>Rolton</surname><given-names>A.</given-names></name>
<name><surname>Vignier</surname><given-names>J.</given-names></name>
</person-group><article-title>Inactivated ostreid herpesvirus-1 induces an innate immune response in the Pacific oyster, Crassostrea gigas, hemocytes</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1161145</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1161145</pub-id><pub-id pub-id-type="pmid">37187746</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00282"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>C.S.</given-names></name>
<name><surname>Estes</surname><given-names>R.M.</given-names></name>
<name><surname>Stokes</surname><given-names>N.A.</given-names></name>
<name><surname>Burge</surname><given-names>C.A.</given-names></name>
<name><surname>Hargove</surname><given-names>J.S.</given-names></name>
<name><surname>Barber</surname><given-names>B.J.</given-names></name>
<name><surname>Elston</surname><given-names>R.A.</given-names></name>
<name><surname>Burreson</surname><given-names>E.M.</given-names></name>
<name><surname>Reece</surname><given-names>K.S.</given-names></name>
</person-group><article-title>Herpes virus in juvenile Pacific oysters Crassostrea gigas from Tomales Bay, California, coincides with summer mortality episodes</article-title><source>Dis. Aquat. Organ.</source><year>2005</year><volume>63</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.3354/dao063033</pub-id><pub-id pub-id-type="pmid">15759798</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00282"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Renault</surname><given-names>T.</given-names></name>
<name><surname>Le Deuff</surname><given-names>R.-M.</given-names></name>
<name><surname>Cochennec</surname><given-names>N.</given-names></name>
<name><surname>Maffart</surname><given-names>P.</given-names></name>
</person-group><article-title>Herpesviruses associated with mortalities among Pacific oyster, Crassostrea gigas, in France-Comparative study</article-title><source>Rev. M&#x000e9;decine V&#x000e9;t&#x000e9;rinaire</source><year>1994</year><volume>145</volume><fpage>735</fpage><lpage>742</lpage></element-citation></ref><ref id="B22-viruses-17-00282"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.N.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>B.W.</given-names></name>
<name><surname>Xin</surname><given-names>L.S.</given-names></name>
<name><surname>Wang</surname><given-names>C.M.</given-names></name>
<name><surname>Bai</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Localization and Tissue Tropism of Ostreid Herpesvirus 1 in Blood Clam Anadara broughtonii</article-title><source>Biology</source><year>2024</year><volume>13</volume><elocation-id>720</elocation-id><pub-id pub-id-type="doi">10.3390/biology13090720</pub-id><pub-id pub-id-type="pmid">39336147</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00282"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imenshahidi</surname><given-names>M.</given-names></name>
<name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name>
</person-group><article-title>Berberis Vulgaris and Berberine: An Update Review</article-title><source>Phytother. Res.</source><year>2016</year><volume>30</volume><fpage>1745</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1002/ptr.5693</pub-id><pub-id pub-id-type="pmid">27528198</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00282"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Fichna</surname><given-names>J.</given-names></name>
<name><surname>Storr</surname><given-names>M.</given-names></name>
</person-group><article-title>Effects of berberine in the gastrointestinal tract&#x02014;A review of actions and therapeutic implications</article-title><source>Am. J. Chin. Med.</source><year>2014</year><volume>42</volume><fpage>1053</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1142/S0192415X14500669</pub-id><pub-id pub-id-type="pmid">25183302</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00282"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arrigoni</surname><given-names>R.</given-names></name>
<name><surname>Ballini</surname><given-names>A.</given-names></name>
<name><surname>Jirillo</surname><given-names>E.</given-names></name>
<name><surname>Santacroce</surname><given-names>L.</given-names></name>
</person-group><article-title>Current View on Major Natural Compounds Endowed with Antibacterial and Antiviral Effects</article-title><source>Antibiotics</source><year>2024</year><volume>13</volume><elocation-id>603</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics13070603</pub-id><pub-id pub-id-type="pmid">39061285</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00282"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solnier</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Kuo</surname><given-names>Y.C.</given-names></name>
<name><surname>Du</surname><given-names>M.</given-names></name>
<name><surname>Roh</surname><given-names>K.</given-names></name>
<name><surname>Gahler</surname><given-names>R.</given-names></name>
<name><surname>Wood</surname><given-names>S.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
</person-group><article-title>Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>2567</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15112567</pub-id><pub-id pub-id-type="pmid">38004546</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00282"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luganini</surname><given-names>A.</given-names></name>
<name><surname>Mercorelli</surname><given-names>B.</given-names></name>
<name><surname>Messa</surname><given-names>L.</given-names></name>
<name><surname>Palu</surname><given-names>G.</given-names></name>
<name><surname>Gribaudo</surname><given-names>G.</given-names></name>
<name><surname>Loregian</surname><given-names>A.</given-names></name>
</person-group><article-title>The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity</article-title><source>Antiviral Res.</source><year>2019</year><volume>164</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.02.006</pub-id><pub-id pub-id-type="pmid">30738836</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00282"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>M.</given-names></name>
<name><surname>Chu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Su</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Downregulation of cellular c-Jun N-terminal protein kinase and NF-kappaB activation by berberine may result in inhibition of herpes simplex virus replication</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>5068</fpage><lpage>5078</lpage><pub-id pub-id-type="doi">10.1128/AAC.02427-14</pub-id><pub-id pub-id-type="pmid">24913175</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00282"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Ekavali</surname></name>
<name><surname>Chopra</surname><given-names>K.</given-names></name>
<name><surname>Mukherjee</surname><given-names>M.</given-names></name>
<name><surname>Pottabathini</surname><given-names>R.</given-names></name>
<name><surname>Dhull</surname><given-names>D.K.</given-names></name>
</person-group><article-title>Current knowledge and pharmacological profile of berberine: An update</article-title><source>Eur. J. Pharmacol.</source><year>2015</year><volume>761</volume><fpage>288</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.05.068</pub-id><pub-id pub-id-type="pmid">26092760</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00282"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
</person-group><article-title>Suppression effect of plant-derived berberine on cyprinid herpesvirus 2 proliferation and its pharmacokinetics in Crucian carp (Carassius auratus gibelio)</article-title><source>Antivir. Res.</source><year>2021</year><volume>186</volume><fpage>105000</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.105000</pub-id><pub-id pub-id-type="pmid">33359191</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00282"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riisg&#x000e5;rd</surname><given-names>H.U.</given-names></name>
<name><surname>Kittner</surname><given-names>C.</given-names></name>
<name><surname>Seerup</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Regulation of opening state and filtration rate in filter-feeding bivalves (Cardium edule, Mytilus edulis, Mya arenaria) in response to low algal concentration</article-title><source>J. Exp. Mar. Biol. Ecol.</source><year>2003</year><volume>284</volume><fpage>105</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/S0022-0981(02)00496-3</pub-id></element-citation></ref><ref id="B32-viruses-17-00282"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schikorski</surname><given-names>D.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
<name><surname>Saulnier</surname><given-names>D.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Moreau</surname><given-names>P.</given-names></name>
<name><surname>P&#x000e9;pin</surname><given-names>J.-F.</given-names></name>
</person-group><article-title>Experimental infection of Pacific oyster Crassostrea gigas spat by ostreid herpesvirus 1: Demonstration of oyster spat susceptibility</article-title><source>Vet. Res.</source><year>2011</year><volume>42</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-42-27</pub-id><pub-id pub-id-type="pmid">21314910</pub-id>
</element-citation></ref><ref id="B33-viruses-17-00282"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shamma</surname><given-names>R.N.</given-names></name>
<name><surname>Latif</surname><given-names>R.</given-names></name>
</person-group><article-title>The potential of synergism between ultrasonic energy and Soluplus <sup>&#x000ae;</sup> as a tool for solubilization and dissolution enhancement of a poorly water soluble drug. A statistically based process optimization</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2018</year><volume>43</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2017.10.023</pub-id></element-citation></ref><ref id="B34-viruses-17-00282"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tong</surname><given-names>C.Y.</given-names></name>
<name><surname>Lew</surname><given-names>J.K.</given-names></name>
<name><surname>Derek</surname><given-names>C.J.C.</given-names></name>
</person-group><article-title>Algal extracellular organic matter pre-treatment enhances microalgal biofilm adhesion onto microporous substrate</article-title><source>Chemosphere</source><year>2022</year><volume>307</volume><issue-part>Pt 1</issue-part><fpage>135740</fpage><pub-id pub-id-type="doi">10.1016/j.chemosphere.2022.135740</pub-id><pub-id pub-id-type="pmid">35850213</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00282"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Ling</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
</person-group><article-title>Mitochondrial apoptotic pathway-mediated suppression of largemouth bass virus proliferation by berberine</article-title><source>Aquaculture</source><year>2024</year><volume>588</volume><fpage>740881</fpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2024.740881</pub-id></element-citation></ref><ref id="B36-viruses-17-00282"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>C.M.</given-names></name>
<name><surname>Rosani</surname><given-names>U.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Xin</surname><given-names>L.S.</given-names></name>
<name><surname>Bortoletto</surname><given-names>E.</given-names></name>
<name><surname>Wegner</surname><given-names>K.M.</given-names></name>
<name><surname>Wang</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Viral Decoys: The Only Two Herpesviruses Infecting Invertebrates Evolved Different Transcriptional Strategies to Deflect Post-Transcriptional Editing</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1971</elocation-id><pub-id pub-id-type="doi">10.3390/v13101971</pub-id><pub-id pub-id-type="pmid">34696401</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00282"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>C.M.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Venier</surname><given-names>P.</given-names></name>
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Y.N.</given-names></name>
<name><surname>Wang</surname><given-names>C.M.</given-names></name>
<name><surname>Xin</surname><given-names>L.S.</given-names></name>
<name><surname>Rosani</surname><given-names>U.</given-names></name>
</person-group><article-title>Paired miRNA and RNA sequencing provides a first insight into molecular defense mechanisms of Scapharca broughtonii during ostreid herpesvirus-1 infection</article-title><source>Fish. Shellfish. Immunol.</source><year>2022</year><volume>122</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2022.02.004</pub-id><pub-id pub-id-type="pmid">35150830</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00282"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xin</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Bai</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>Validation of housekeeping genes for quantitative mRNA expression analysis in OsHV-1 infected ark clam, Scapharca broughtonii</article-title><source>J. Invertebr. Pathol.</source><year>2018</year><volume>155</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.jip.2018.04.011</pub-id><pub-id pub-id-type="pmid">29723493</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00282"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segarra</surname><given-names>A.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Pepin</surname><given-names>J.F.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Transcriptomic study of 39 ostreid herpesvirus 1 genes during an experimental infection</article-title><source>J. Invertebr. Pathol.</source><year>2014</year><volume>119</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jip.2014.03.002</pub-id><pub-id pub-id-type="pmid">24681357</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00282"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Livak</surname><given-names>K.J.</given-names></name>
<name><surname>Schmittgen</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00282"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oden</surname><given-names>E.</given-names></name>
<name><surname>Martenot</surname><given-names>C.</given-names></name>
<name><surname>Berthaux</surname><given-names>M.</given-names></name>
<name><surname>Travaill&#x000e9;</surname><given-names>E.</given-names></name>
<name><surname>Malas</surname><given-names>J.P.</given-names></name>
<name><surname>Houssin</surname><given-names>M.</given-names></name>
</person-group><article-title>Quantification of ostreid herpesvirus 1 (OsHV-1) in Crassostrea gigas by real-time PCR: Determination of a viral load threshold to prevent summer mortalities</article-title><source>Aquaculture</source><year>2011</year><volume>317</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2011.04.001</pub-id></element-citation></ref><ref id="B42-viruses-17-00282"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morga</surname><given-names>B.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Guesdon</surname><given-names>S.</given-names></name>
<name><surname>Chollet</surname><given-names>B.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Haemocytes from Crassostrea gigas and OsHV-1: A promising in vitro system to study host/virus interactions</article-title><source>J. Invertebr. Pathol.</source><year>2017</year><volume>150</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jip.2017.09.007</pub-id><pub-id pub-id-type="pmid">28911815</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00282"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Ye</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>Research progress on antiviral constituents in traditional Chinese medicines and their mechanisms of action</article-title><source>Pharm. Biol.</source><year>2022</year><volume>60</volume><fpage>1063</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1080/13880209.2022.2074053</pub-id><pub-id pub-id-type="pmid">35634712</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00282"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warowicka</surname><given-names>A.</given-names></name>
<name><surname>Nawrot</surname><given-names>R.</given-names></name>
<name><surname>Gozdzicka-Jozefiak</surname><given-names>A.</given-names></name>
</person-group><article-title>Antiviral activity of berberine</article-title><source>Arch. Virol.</source><year>2020</year><volume>165</volume><fpage>1935</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1007/s00705-020-04706-3</pub-id><pub-id pub-id-type="pmid">32594322</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00282"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>L.</given-names></name>
</person-group><article-title>Downregulation of NF-&#x003ba;B signaling is involved in berberine-mediated protection of crucian carp (<italic toggle="yes">Carassius auratus gibelio</italic>) from cyprinid herpesvirus 2 infection</article-title><source>Aquaculture</source><year>2022</year><volume>548</volume><fpage>737713</fpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2021.737713</pub-id></element-citation></ref><ref id="B46-viruses-17-00282"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suryavanshi</surname><given-names>S.V.</given-names></name>
<name><surname>Kulkarni</surname><given-names>Y.A.</given-names></name>
</person-group><article-title>NF-kappabeta: A Potential Target in the Management of Vascular Complications of Diabetes</article-title><source>Front. Pharmacol.</source><year>2017</year><volume>8</volume><elocation-id>798</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2017.00798</pub-id><pub-id pub-id-type="pmid">29163178</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00282"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Ma</surname><given-names>T.</given-names></name>
</person-group><article-title>Berberine prevents lethal EV71 neurological infection in newborn mice</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>1027566</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.1027566</pub-id><pub-id pub-id-type="pmid">36386168</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00282"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hung</surname><given-names>T.C.</given-names></name>
<name><surname>Jassey</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>C.H.</given-names></name>
<name><surname>Lin</surname><given-names>C.J.</given-names></name>
<name><surname>Lin</surname><given-names>C.C.</given-names></name>
<name><surname>Wong</surname><given-names>S.H.</given-names></name>
<name><surname>Wang</surname><given-names>J.Y.</given-names></name>
<name><surname>Yen</surname><given-names>M.H.</given-names></name>
<name><surname>Lin</surname><given-names>L.T.</given-names></name>
</person-group><article-title>Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein</article-title><source>Phytomedicine</source><year>2019</year><volume>53</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2018.09.025</pub-id><pub-id pub-id-type="pmid">30668413</pub-id>
</element-citation></ref><ref id="B49-viruses-17-00282"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martenot</surname><given-names>C.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Morga</surname><given-names>B.</given-names></name>
<name><surname>Degremont</surname><given-names>L.</given-names></name>
<name><surname>Lamy</surname><given-names>J.B.</given-names></name>
<name><surname>Houssin</surname><given-names>M.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
</person-group><article-title>Exploring First Interactions Between Ostreid Herpesvirus 1 (OsHV-1) and Its Host, Crassostrea gigas: Effects of Specific Antiviral Antibodies and Dextran Sulfate</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>1128</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.01128</pub-id><pub-id pub-id-type="pmid">31178841</pub-id>
</element-citation></ref><ref id="B50-viruses-17-00282"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Yao</surname><given-names>M.</given-names></name>
<name><surname>Xin</surname><given-names>L.</given-names></name>
<name><surname>Bai</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>Characterization of Host Cell Potential Proteins Interacting with OsHV-1 Membrane Proteins</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2518</elocation-id><pub-id pub-id-type="doi">10.3390/v13122518</pub-id><pub-id pub-id-type="pmid">34960787</pub-id>
</element-citation></ref><ref id="B51-viruses-17-00282"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lepretre</surname><given-names>M.</given-names></name>
<name><surname>Faury</surname><given-names>N.</given-names></name>
<name><surname>Segarra</surname><given-names>A.</given-names></name>
<name><surname>Claverol</surname><given-names>S.</given-names></name>
<name><surname>Degremont</surname><given-names>L.</given-names></name>
<name><surname>Palos-Ladeiro</surname><given-names>M.</given-names></name>
<name><surname>Armengaud</surname><given-names>J.</given-names></name>
<name><surname>Renault</surname><given-names>T.</given-names></name>
<name><surname>Morga</surname><given-names>B.</given-names></name>
</person-group><article-title>Comparative Proteomics of Ostreid Herpesvirus 1 and Pacific Oyster Interactions With Two Families Exhibiting Contrasted Susceptibility to Viral Infection</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>621994</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.621994</pub-id><pub-id pub-id-type="pmid">33537036</pub-id>
</element-citation></ref><ref id="B52-viruses-17-00282"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>T.J.</given-names></name>
<name><surname>Rolland</surname><given-names>J.L.</given-names></name>
<name><surname>Vergnes</surname><given-names>A.</given-names></name>
<name><surname>Raftos</surname><given-names>D.</given-names></name>
<name><surname>Montagnani</surname><given-names>C.</given-names></name>
</person-group><article-title>OsHV-1 countermeasures to the Pacific oyster's anti-viral response</article-title><source>Fish. Shellfish. Immunol.</source><year>2015</year><volume>47</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2015.09.025</pub-id><pub-id pub-id-type="pmid">26384844</pub-id>
</element-citation></ref><ref id="B53-viruses-17-00282"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosani</surname><given-names>U.</given-names></name>
<name><surname>Bortoletto</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>B.W.</given-names></name>
<name><surname>Xin</surname><given-names>L.S.</given-names></name>
<name><surname>Krupovic</surname><given-names>M.</given-names></name>
<name><surname>Bai</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Long-read transcriptomics of Ostreid herpesvirus 1 uncovers a conserved expression strategy for the capsid maturation module and pinpoints a mechanism for evasion of the ADAR-based antiviral defence</article-title><source>Virus Evol.</source><year>2024</year><volume>10</volume><fpage>veae088</fpage><pub-id pub-id-type="doi">10.1093/ve/veae088</pub-id><pub-id pub-id-type="pmid">39555210</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00282-f001"><label>Figure 1</label><caption><p>Survival rate of OsHV-1-infected blood clams treated with various concentrations of BBH. At 96 h post-OsHV-1 infection, the survival rates of blood clams treated with 1 mg/L, 3 mg/L, 6 mg/L, and 9 mg/L BBH baths were 23.33%, 46.67%, 43.33%, and 33.33%, respectively, while the survival rate of blood clams in the control group (without drug exposure) was 0%.</p></caption><graphic xlink:href="viruses-17-00282-g001" position="float"/></fig><fig position="float" id="viruses-17-00282-f002"><label>Figure 2</label><caption><p>OsHV-1 DNA copy numbers in the 3 mg/L BBH bath group and the control group. The average OsHV-1 DNA copy numbers (copies/ng DNA) in the control group and the medicated bath group from 12 to 72 h post-infection were as follows: 0.08 vs. 0.02 (12 h), 37.19 vs. 0.07 (24 h), 4.97 &#x000d7; 10<sup>2</sup> vs. 1.43 &#x000d7; 10<sup>2</sup> (36 h), 3.28 &#x000d7; 10<sup>4</sup> vs. 6.67 &#x000d7; 10<sup>3</sup> (48 h), 3.97 &#x000d7; 10<sup>4</sup> vs. 1.38 &#x000d7; 10<sup>4</sup> (60 h), and 5.38 &#x000d7; 10<sup>4</sup> vs. 2.25 &#x000d7; 10<sup>4</sup> (72 h). * <italic toggle="yes">p</italic> &#x0003c; 0.05 and *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="viruses-17-00282-g002" position="float"/></fig><fig position="float" id="viruses-17-00282-f003"><label>Figure 3</label><caption><p>Bubble chart showing the relative expression levels of 26 OsHV-1 ORFs in the 3 mg/L berberine hydrochloride immersion group and the control group. At 24, 48, and 72 h post-infection, the relative expression levels of 26 OsHV-1 ORFs from five genomic/family groups were measured in both the 3 mg/L berberine hydrochloride immersion group and the control group. The color indicates the significance level of gene expression, with red representing higher significance and blue representing lower significance.</p></caption><graphic xlink:href="viruses-17-00282-g003" position="float"/></fig><fig position="float" id="viruses-17-00282-f004"><label>Figure 4</label><caption><p>Bar graph showing the relative expression levels of OsHV-1 ORFs. At different time points of viral infection (24 h, 48 h, and 72 h), the relative expression levels of OsHV-1 ORF7, ORF25, ORF36, ORF72, ORF80, and ORF104 in the experimental group (3 mg/L berberine hydrochloride treatment) and the control group (no drug exposure) were normalized for comparison. Statistical significance was assessed using multiple t-tests, with * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, and *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="viruses-17-00282-g004a" position="float"/><graphic xlink:href="viruses-17-00282-g004b" position="float"/></fig><table-wrap position="float" id="viruses-17-00282-t001"><object-id pub-id-type="pii">viruses-17-00282-t001_Table 1</object-id><label>Table 1</label><caption><p>Primer information for OsHV-1 open reading frames (ORFs) and blood clam housekeeping genes used in RT-qPCR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Forward Primer<break/>(5&#x02032;&#x02013;3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reverse Primer<break/>(5&#x02032;&#x02013;3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amplicon Length<break/>(bp)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Function</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF7</td><td align="center" valign="middle" rowspan="1" colspan="1">CGATAGCGAGGGAGACGATG</td><td align="center" valign="middle" rowspan="1" colspan="1">CCGTGTGTTCCATTCTGCAA</td><td align="center" valign="middle" rowspan="1" colspan="1">198</td><td align="center" valign="middle" rowspan="1" colspan="1">DNA primase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF9</td><td align="center" valign="middle" rowspan="1" colspan="1">CCATCCTCGTTGGGGGTAAT</td><td align="center" valign="middle" rowspan="1" colspan="1">CGTGGCATGTGAGCAGAGAG</td><td align="center" valign="middle" rowspan="1" colspan="1">189</td><td align="center" valign="middle" rowspan="1" colspan="1">RING finger protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF11</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCGTGGAGAGTTCATCAAGGT</td><td align="center" valign="middle" rowspan="1" colspan="1">TTGCCGCATCTGCCAATGGT</td><td align="center" valign="middle" rowspan="1" colspan="1">201</td><td align="center" valign="middle" rowspan="1" colspan="1">Unknown protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF16</td><td align="center" valign="middle" rowspan="1" colspan="1">TCCAAACCCAGACCCAGCTT</td><td align="center" valign="middle" rowspan="1" colspan="1">CCAAAGAGCAGGCCAGGGTA</td><td align="center" valign="middle" rowspan="1" colspan="1">148</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF20</td><td align="center" valign="middle" rowspan="1" colspan="1">CTGGCTGTTCTGCCATTTCC</td><td align="center" valign="middle" rowspan="1" colspan="1">AGACAGCGGCAAGGTGATGT</td><td align="center" valign="middle" rowspan="1" colspan="1">213</td><td align="center" valign="middle" rowspan="1" colspan="1">Ribonucleotide reductase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF25</td><td align="center" valign="middle" rowspan="1" colspan="1">CTCGCCAAAGGTCGTATCCA</td><td align="center" valign="middle" rowspan="1" colspan="1">CCACAAGGGTGAATTCCATGTT</td><td align="center" valign="middle" rowspan="1" colspan="1">200</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF27</td><td align="center" valign="middle" rowspan="1" colspan="1">ACCGCCCATGGTGCTAATTC</td><td align="center" valign="middle" rowspan="1" colspan="1">CCTGCAAGGCCAAGTATGGA</td><td align="center" valign="middle" rowspan="1" colspan="1">189</td><td align="center" valign="middle" rowspan="1" colspan="1">dUTPase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF34</td><td align="center" valign="middle" rowspan="1" colspan="1">CTTGGACAAATGCATCCCAAA</td><td align="center" valign="middle" rowspan="1" colspan="1">TGGCACCCACATTCAAGGTT</td><td align="center" valign="middle" rowspan="1" colspan="1">183</td><td align="center" valign="middle" rowspan="1" colspan="1">dUTPase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF36</td><td align="center" valign="middle" rowspan="1" colspan="1">AGAGACAGGCATGGCAGAGAGT</td><td align="center" valign="middle" rowspan="1" colspan="1">ACTTCTTGGAATCGGTCCTCGG</td><td align="center" valign="middle" rowspan="1" colspan="1">122</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF37</td><td align="center" valign="middle" rowspan="1" colspan="1">CAACCGACAATTCCCTCCCGAT</td><td align="center" valign="middle" rowspan="1" colspan="1">CACCAGCCCGCGTTAAGACAT</td><td align="center" valign="middle" rowspan="1" colspan="1">122</td><td align="center" valign="middle" rowspan="1" colspan="1">Unknown protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF41</td><td align="center" valign="middle" rowspan="1" colspan="1">AACCGTGTGTCCCACCATTC</td><td align="center" valign="middle" rowspan="1" colspan="1">ACCGCAGTGCAACTCCAATC</td><td align="center" valign="middle" rowspan="1" colspan="1">183</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF42</td><td align="center" valign="middle" rowspan="1" colspan="1">GCAGGCATAACAGGTGAGCA</td><td align="center" valign="middle" rowspan="1" colspan="1">TGAGAGGCGTGACAGGGAAT</td><td align="center" valign="middle" rowspan="1" colspan="1">205</td><td align="center" valign="middle" rowspan="1" colspan="1">BIR protein containing RING finger</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF49</td><td align="center" valign="middle" rowspan="1" colspan="1">ACCCAAAGTCGGTGGGGTAA</td><td align="center" valign="middle" rowspan="1" colspan="1">CGGAGATTTGCGGTGTACCA</td><td align="center" valign="middle" rowspan="1" colspan="1">191</td><td align="center" valign="middle" rowspan="1" colspan="1">Helicase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF51</td><td align="center" valign="middle" rowspan="1" colspan="1">CGGCAAGGGAGATTGACCACAA</td><td align="center" valign="middle" rowspan="1" colspan="1">ACCAATTCAGGCACTGGCTTCC</td><td align="center" valign="middle" rowspan="1" colspan="1">268</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I ribonucleotide reductase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF53</td><td align="center" valign="middle" rowspan="1" colspan="1">CCGAAAAACCAGGGACTGGA</td><td align="center" valign="middle" rowspan="1" colspan="1">TGGGCGGGAAGTAGATCGTT</td><td align="center" valign="middle" rowspan="1" colspan="1">197</td><td align="center" valign="middle" rowspan="1" colspan="1">RING finger protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF54</td><td align="center" valign="middle" rowspan="1" colspan="1">TAACCATGGGCACCGAAGAC</td><td align="center" valign="middle" rowspan="1" colspan="1">ACATCTCGCCGCTTTGTCAC</td><td align="center" valign="middle" rowspan="1" colspan="1">193</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I membrane glycoprotein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF57</td><td align="center" valign="middle" rowspan="1" colspan="1">TTACCAGCACCGAGCAGGAT</td><td align="center" valign="middle" rowspan="1" colspan="1">TCGCCGCTTTTATCCAACAC</td><td align="center" valign="middle" rowspan="1" colspan="1">150</td><td align="center" valign="middle" rowspan="1" colspan="1">Multiple transmembrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF59</td><td align="center" valign="middle" rowspan="1" colspan="1">ACGATGACGGAGATGGAGTTGT</td><td align="center" valign="middle" rowspan="1" colspan="1">AGTGATTGGAGGTTGTGGAGGT</td><td align="center" valign="middle" rowspan="1" colspan="1">281</td><td align="center" valign="middle" rowspan="1" colspan="1">Multiple transmembrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF67</td><td align="center" valign="middle" rowspan="1" colspan="1">GATGACGGCATTGGTGAGGT</td><td align="center" valign="middle" rowspan="1" colspan="1">CCTGTGTTGCGGCTTGGTTA</td><td align="center" valign="middle" rowspan="1" colspan="1">195</td><td align="center" valign="middle" rowspan="1" colspan="1">SF2 helicase (Enzyme)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF68</td><td align="center" valign="middle" rowspan="1" colspan="1">TTGGTACCGGCCATTGACAT</td><td align="center" valign="middle" rowspan="1" colspan="1">GGAACCGAGTTTGCCACCTT</td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I membrane glycoprotein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF72</td><td align="center" valign="middle" rowspan="1" colspan="1">ACCTCCCCGTCAATGGTATGA</td><td align="center" valign="middle" rowspan="1" colspan="1">TCCACCACACCCCTACAATCA</td><td align="center" valign="middle" rowspan="1" colspan="1">180</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF80</td><td align="center" valign="middle" rowspan="1" colspan="1">GGATTGGTGCAACAGTATTGGC</td><td align="center" valign="middle" rowspan="1" colspan="1">TTCGATGCCTTGCCGGTGAT</td><td align="center" valign="middle" rowspan="1" colspan="1">130</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF84</td><td align="center" valign="middle" rowspan="1" colspan="1">CATCTGTGCTGTCATCGTCCA</td><td align="center" valign="middle" rowspan="1" colspan="1">TGTACACCTCGGTGCAGGTTTT</td><td align="center" valign="middle" rowspan="1" colspan="1">186</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF87</td><td align="center" valign="middle" rowspan="1" colspan="1">CACAGACGACATTTCCCCAAA</td><td align="center" valign="middle" rowspan="1" colspan="1">AAAGCTCGTTCCCACATTGGT</td><td align="center" valign="middle" rowspan="1" colspan="1">196</td><td align="center" valign="middle" rowspan="1" colspan="1">BIR protein containing RING finger</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF88</td><td align="center" valign="middle" rowspan="1" colspan="1">CCAACAGATGTGGTGAGCGGTA</td><td align="center" valign="middle" rowspan="1" colspan="1">TGGTGGCGGTGGTGGTGAAT</td><td align="center" valign="middle" rowspan="1" colspan="1">152</td><td align="center" valign="middle" rowspan="1" colspan="1">Class I membrane protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ORF104</td><td align="center" valign="middle" rowspan="1" colspan="1">AGGCAGCCATTGAAGCAGAGTC</td><td align="center" valign="middle" rowspan="1" colspan="1">GCGGTGTTGTCAGAGGTGGTAA</td><td align="center" valign="middle" rowspan="1" colspan="1">289</td><td align="center" valign="middle" rowspan="1" colspan="1">Capsid protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EF-1&#x003b1;</td><td align="center" valign="middle" rowspan="1" colspan="1">TTAGACGCAATCCTCCCTCC</td><td align="center" valign="middle" rowspan="1" colspan="1">TAACGACGGTTCCTGGTTTG</td><td align="center" valign="middle" rowspan="1" colspan="1">142</td><td align="center" valign="middle" rowspan="1" colspan="1">Housekeeping gene</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RL15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AGACCAGACAAAGCCAGAAGAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GCTGAAGTAAGTCCACGCATT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Housekeeping gene</td></tr></tbody></table></table-wrap></floats-group></article>